Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 3/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6978927 | 0.86 | PER2 (0.43) | PER2CRY2PIK3CDRAB9AKMT2A | |
| SCHEMBL8015523 | 0.83 | PIK3CD (0.45) | PER2ADRA1BADRA1APIK3CDRAB9A | |
| SCHEMBL23854068 | 0.82 | PIK3CD (0.46) | PER2CRY2PIK3CDKMT2ATSHR | |
| Glycerin SCHEMBL8755808 | 0.81 | GAA (0.44) | ADRA1BADRA1APIK3CDRAB9AKMT2A | |
| Glycerin SCHEMBL5157225 | 0.81 | GAA (0.44) | ADRA1BADRA1APIK3CDRAB9AKMT2A | |
| SCHEMBL8071932 | 0.80 | ADRA1B (0.43) | ADRA1BADRA1APIK3CDRAB9AKMT2A | |
| SCHEMBL10981771 | 0.80 | ADRA1B (0.43) | ADRA1BADRA1APIK3CDRAB9AKMT2A | |
| SCHEMBL8019321 | 0.80 | POLB (0.44) | RAB9AKMT2AALDH1A1TSHR | |
| SCHEMBL8538168 | 0.79 | KMT2A (0.44) | ADRA1BADRA1APIK3CDRAB9AKMT2A | |
| Laurocapram SCHEMBL16238107 | 0.78 | GAA (0.45) | ADRA1BPIK3CDRAB9AKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6133274-A | TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS | CELL THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6121270-A | N-(EPOXYALKYL)XANTHINE DERIVATIVES WHICH MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI | CELL THERAPEUTICS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-5866576-A | COMPOUNDS THAT ACT AS DRUGS ON THE CELLULAR AND BIOCHEMICAL LEVEL TO MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI. | CELL THERAPEUTICS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0662834-A4 | NOVEL EPOXIDE-CONTAINING COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0662834-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994006431-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-31 | — | — | WO | disclosed |